

5 February 2010

QUEST FOR GROWTH

FY09 sees return to profit and record RoE

INVESTMENT COMPANIES

BELGIUM

CURRENT PRICE €4.50

TARGET PRICE €5.25

ACCUMULATE
 RATING UNCHANGED

Performance over	1M	3M	12M
Absolute	-6%	1%	58%
Rel. BEL20	-2%	-1%	23%
12m Hi/Lo		€ 4.89/2.80	
Bloomberg		QFG BB	
Reuters		QUFG.BR	
Market Cap		€ 43m	
Next corporate event			
General Assembly 09: 18 March 2010			
www.questforgrowth.com			

FY/e 31.12	2006	2007	2008	2009
Net result (group)	21.5	0.6	-48.4	18.1
Adjusted net result	21.5	0.6	-48.4	18.1
Basic EPS (€)	2.28	0.05	-4.11	1.53
Total return	20.4%	3.4%	-61.9%	47.6%
Return on Equity (avg)	20.9%	0.6%	-41.8%	26.8%
Adjusted equity value	12.42	9.87	9.87	7.25
Premium (-)/ Discount	19.5%	14.9%	14.9%	35.9%
Dividend per share	1.94	0.05	0.00	0.00
Dividend yield	19.4%	0.6%	0.0%	0.0%

Source: KBC Securities

Quest reported FY09 profit of € 18.1m, thanks partly to strong equity markets that helped the company realise a €12.7m profit in 2H09. The positive result comes entirely on the back of gains made in the listed portfolio, as write-downs and capital gains cancelled each other out in the PE part of the portfolio. NAV at end-FY09 climbed to € 7.25 (+27%), while the stock rose to € 4.65 (+47.6% y/y). No dividend will be paid due to the carried-over losses still on the balance sheet. Quest's valuation at current trading levels is undemanding; this in our view is due to the absence of stock price triggers that can lift the equity value and continuing uncertainty about the stability of the valuation of the direct PE portfolio.

NICHE MARKET POSITIONING PAYS OFF FOR LISTED STOCKS, PE WEIGHT SHRINKS

- FY09 profit.** NAV increased 27% y/y, a figure that was reported ahead of – and as such acted as guidance for – the actual FY09 results. The share soared 47.6% in FY09 to arrive at € 4.65, reducing the discount to 35.8%. ROE was pushed into the black, climbing to 26.8% (-41.8% in FY08).
- Listed portfolio is the driver.** The positive result came almost entirely on the back of the listed investment portfolio, which performed much better than both of Quest's benchmark indices (Bloomberg New Markets 50 and the euro-denominated Nasdaq). The unquoted portfolio's valuation was affected by gains (Certess (IRR of 35%), Movetis (IPO), Clear2Pay (cap hike), as well as losses (iNEWiT (€ 0.12m), CoreOptics (€ 1.67bn), Concept Group (€ 0.07m), Idea (€ 0.52m), Mapper (€ 0.21m) and Trigen (€ 0.11m), Active Circle (€ 0.80m). In terms of investments, FY09 saw the addition of TC Land Expression (€ 0.75m), Kiadis Pharma (€ 0.30m), CoreOptics (€ 0.52m) and Clear2Pay (€ 0.29m).
- Lack of triggers explains undervaluation.** The stock is currently trading at a 38.8% discount to NAV of € 7.36. While it's true that this level is relatively high for a dynamic investment company such as Quest, we think it is justified given a long series of writedowns in the Private Equity portfolio and the fact that we see few chances to create value via exits (IPO or trade sale). Accumulate rating maintained with a € 5.25 target price.

ANALYSTS

Tom Simonts

Financial Analyst - Brussels

+32 2 429 37 22

tom.simonts@kbcsecurities.be

5 February 2010

INVESTMENT CASE

We currently estimate Quest's NAV at € 7.36 per share, pointing to a discount of 38.8%. Although this is north of the 30% average discount level, it doesn't automatically mean Quest is a bargain. Its listed portfolio is well-diversified in – and even heavily skewed towards - niche markets such as Cleantech and New Materials, a positioning that despite being more vulnerable to volatility bodes well for FY10. But since unlocking value via the Movetis IPO and the capital hike at Clear2Pay, Quest has few triggers left to boost NAV; divesting or floating assets out of the Private Equity portfolio appears unlikely due to a lack of M&A candidates. We believe these factors justify both caution and a need for tangible proof that value can be created in the core PE segment. We stick to our Accumulate rating and € 5.25 TP, which implies a discount of 28.6% to adjusted equity value and leaves upside potential of 16.6%.

2H09 NET PROFIT OF €12.7M


Quest booked a FY09 profit of € 18.08m (€ 1.53 p.s.), reversing a huge FY08 loss of € 48.40m (€ 4.10 p.s.). The figure comes as no surprise, since a 27.0% y/y increase in NAV was reported at end-FY09 (€ 7.25 p.s., versus € 5.71 at end-FY08). RoE moved into the black again, arriving at 26.8% (-41.8% in FY08). Although positive, Quest's NAV growth undershot the overall performance of the benchmark equity indices it compares itself with (euro-denominated Nasdaq Composite and Bloomberg New Markets 50). This is explained by the difference between the return on listed assets (very positive) and Private Equity assets (marginally positive).

INCOME STATEMENT (B-GAAP, €M)

	FY07	1H08	2H08	FY08	1H09	2H09	FY09	% y/y
Gross operating income	3.1	-17.7	-28.2	-45.9	5.7	13.4	19.1	-141.7%
Depreciation and write-downs	-0.2	0.0	0.0	0.0	0.0	0.0	0.0	-
Other operating charges	-2.6	-1.4	-1.3	-2.7	-1.1	-1.1	-2.3	-15.1%
Operating result	0.3	-19.1	-29.5	-48.6	4.6	12.3	16.9	-134.7%
Financial income	1.5	1.4	0.3	1.6	0.8	0.2	1.0	-36.7%
Financial charges	-1.2	-0.6	-0.8	-1.4	0.0	0.2	0.2	-113.6%
Result on ordinary activities (pre-tax)	0.6	-18.3	-30.1	-48.4	5.4	12.7	18.1	-137.3%
Extraordinary charges	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-
Result (pre-tax)	0.6	-18.3	-30.1	-48.4	5.4	12.7	18.1	-137.3%
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-146.8%
Result for the period	0.6	-18.3	-30.1	-48.4	5.4	12.7	18.1	-137.3%
per share	0.05	-1.55	-2.55	-4.11	0.46	1.08	1.53	-142.2%


Source: KBC Securities

2Q09 BREAKS LONG SERIES OF LOSSES



Source: KBC Securities

ROE MOVING INTO POSITIVE TERRITORY AGAIN



Source: KBC Securities

5 February 2010

NAV INCREASE PUMPS UP BALANCE SHEET


Since Private Equity assets barely added to FY09 profit, Quest's balance sheet was positively impacted by changes in the valuation of the listed portfolio alone. Total assets at end-FY09 lag both the 1H08 level and what management believe to be a critical minimum of € 100m. Reported net equity of € 85.4m breaks down as issued capital (€ 109.75m), reserves (€ 2.25m) and carried-over losses (€ 26.56m). This means Quest is not in a position to pay out dividends or to allocate fresh capital to a share buyback program. NAV would need to rise by approx. 30% in FY10 in order to wipe out carried over losses.

BALANCE SHEET (IFRS, €M)

	1H07	FY07	1H08	FY08	1H09	FY09	% y/y
Financial assets	118.3	108.9	83.3	61.1	63.6	79.9	30.6%
Amounts receivable within 1 year	0.2	0.3	0.3	0.2	0.1	0.4	69.9%
Own shares	1.4	1.7	1.6	0.8	1.0	1.2	47.6%
Term deposits	6.1	5.2	10.1	0.0	2.2	2.3	-
Cash at bank and in hand	1.2	0.3	0.9	5.2	6.2	1.8	-65.2%
Deferred charges and accrued income	2.7	0.1	2.6	0.3	0.6	0.1	-81.0%
Total assets	129.8	116.5	98.8	67.7	73.6	85.6	26.4%
Capital and reserves	126.8	115.8	97.5	67.4	72.7	85.4	26.8%
Amounts payable within 1 year	0.7	0.6	0.1	0.1	0.1	0.1	-13.2%
Accrued charges and deferred income	2.3	0.1	1.2	0.2	0.8	0.1	-76.9%
Total liabilities	129.8	116.5	98.8	67.7	73.6	85.6	26.4%


Source: KBC Securities

EVOLUTION OF EQUITY



Source: KBC Securities

NET EQUITY EXPOSURE (% OF NAV)



Source: Quest for Growth

JANUARY NAV UPDATE

Quest on 3 February reported that NAV at end-January climbed to € 7.29 per share, versus € 7.25 at end-December (+0.6% m/m, +28.8% y/y). The stock dropped to € 4.53 (-2.6% m/m, +64.1% y/y), due to which the discount increased slightly to 37.9%. Quest in January made some changes to its listed portfolio, upping stakes in INIT Innovation in Traffic Systems, Selonger.com, Faiveley, Vestas Wind Systems and Centrotec and lowered positions in VizRT, EVS, TKH Group and Solar Millenium. We have adjusted our SOTP model to reflect these changes. Combined, the listed portfolio totals € 52.93m and accounts for 61.0% of NAV. The value of the direct Private Equity stakes wasn't subject to changes and there was no important activity in the 3rd Party fund portfolio either. The direct and indirect PE portfolios are valued at a respective € 16.0m and € 8.3m.

5 February 2010

INVESTMENT PORTFOLIO

Adjusted for the price variation of both the stock price and the underlying assets in February, we currently estimate the portfolio's total value at €86.7m with NAV per share amounting to €7.36. The official figure hovers south of our NAV estimate, due to a lock-up discount to the Movetis stake that shaves off around €0.9 p.s. of the official NAV estimate. Our SOTP model, however, applies actual market values.

SUM-OF-THE-PARTS VALUATION

Description	Sector/market	BB	Shares held	Recent change	Last price	Cmncy	% of NAV	Valuation (€)
Quoted companies							15.42%	13.38
Software & Services								
INIT	Deutsche Börse	IXX GY	100,000	10,000	10.6	€	1.22%	1.06
NEMETSCHEK	Deutsche Börse	NEM GR	142,500	0	16.2	€	2.66%	2.31
SELOGER.COM	Euronext Paris	SLG.FP	35,000	19,400	24.4	€	0.98%	0.85
TELEPERFORMANCE	Euronext Paris	RCF FP	40,000	5,000	24.5	€	1.13%	0.98
TRANSICS	Euronext Brussels	TRAN BB	250,000	0	6.9	€	1.99%	1.73
UNIT 4 AGRESSO	Euronext Amsterdam	U4AGR NA	200,000	0	16.9	€	3.90%	3.38
VIZRT	Deutsche Börse	VIZ GR	315,191	-100,000	2.6	€	0.95%	0.83
WIRECARD	Deutsche Börse	WDI GR	250,000	0	9.0	€	2.59%	2.25
Technology Hardware							11.47%	9.95
EVS BROADCAST	Euronext Brussels	EVS BB	60,000	-8,500	45.8	€	3.17%	2.75
LEM HOLDING	Zwitzerland	LEHN SW	10,000	0	320.0	CHF	2.51%	2.17
TANDBERG	Oslo	TAA NO	140,000	0	166.5	NOK	3.28%	2.85
TKH GROUP	Euronext Amsterdam	TWEKA NA	165,342	-35,000	13.2	€	2.51%	2.18
Pharma & Biotech							11.28%	9.78
ABLXNX	Euronext Brussels	ABLX BB	62,500	0	8.0	€	0.58%	0.50
MOVETIS*	Pharma & Biotech	MOVE BB	523,601	0	13.0	€	7.85%	6.81
ROCHE HOLDINGS	SWX Swiss Exchange	ROG VX	17,500	0	175.5	CHF	2.41%	2.09
WILEX*	Pharma & Biotech		100,000	0	3.9	€	0.45%	0.39
Health Care Equipment & Svs							2.56%	2.22
UNITED DRUG	Dublin	UGD ID	1,000,000	0	2.2	€	2.56%	2.22
Electrical & Engineering							17.19%	14.91
ANDRITZ	Vienna	ANDR AV	80,000	0	41.3	€	3.81%	3.31
ARCADIS	Euronext Amsterdam	ARCAD NA	230,000	0	16.0	€	4.23%	3.67
FAIVELEY	Euronext Paris	LEY FP	20,000	5,000	58.0	€	1.34%	1.16
IMTECH	Euronext Brussels		75,000	0	19.6	€	1.69%	1.47
PFEIFFER VACUUM TECHNOLOG	Deutsche Börse	PFV GR	40,000	0	59.0	€	2.72%	2.36
SMA SOLAR	Deutsche Börse	S92 GY	14,000	0	81.5	€	1.32%	1.14
SOLAR MILLENNIUM	Deutsche Börse	S2M GR	32,500	-7,500	31.4	€	1.18%	1.02
VESTAS WIND SYSTEMS	Copenhagen		21,500	2,500	273.5	DKK	0.91%	0.79
Materials							5.66%	4.91
CENTROTEC	Deutsche Börse	CEV GY	95,000	15,000	12.5	€	1.37%	1.19
GEBERIT	SWX Swiss Exchange	GEBN VX	12,000	0	190.0	€	1.79%	1.55
UMICORE	Euronext Brussels	UMI BB	100,000	0	21.7	€	2.50%	2.17
Loan notes							2.49%	2.16
Private Equity investments			Asset type	Invested	Committed		28.04%	24.32
ACTIVE CIRCLE	Software & Services		equity	0.80		€	0.92%	0.80
CLEAR2PAY	Software & Services		equity	5.36	0.21	€	6.18%	5.36
COREOPTICS	Technology Hardware		equity	1.32		\$	1.53%	1.32
IDEA	Pharma & Biotech		equity	0.52		€	0.60%	0.52
KIADIS	Pharma & Biotech		equity	2.00		€	2.31%	2.00
MAGWELL	Software & Services		equity	0.43		€	0.50%	0.43
PROSONIX	Pharma & Biotech		equity	1.24		£	1.43%	1.24
SPHERE MEDICAL HOLDING	Pharma & Biotech		equity	1.15		£	1.32%	1.15
SYNTAXIN	Pharma & Biotech		equity	1.72		£	1.98%	1.72
TCLAND	Pharma & Biotech		equity	1.50		€	1.73%	1.50
THIRD PARTY INV FUNDS	Various		Funds	8.28	8.12	€	9.55%	8.28
Portfolio							94.10%	81.63
Net cash							5.90%	5.11
Adjusted equity value							100.00%	86.74
Number of shares (outstanding)								11,789,255
Treasury shares (for remuneration purposes, resale, collateral,...)							2.20%	259,305
Treasury shares (available for cancellation)							0.00%	0
Number of shares (for per share calculation)								11,789,255
Quest for Growth last price								4.50
Adjusted equity value p.s.								7.36
Current discount								38.84%
Target prices								
Target equity value								86.74
Target equity value p.s.								7.36
Discount to target equity value								38.84%

KBCS has an ACCUMULATE recommendation and a €5.25 target price.

The upside potential versus a stock price of €4.5 equals 16.67%.


The implied discount of our €5.25 target price vs. the target equity value is 28.65%.

Source: KBC Securities

5 February 2010


The investment portfolio breaks down in net cash (€ 5.1 m, 5.90% of equity), listed assets (€ 52.9m, 61% of equity), the Private Equity portfolio (€ 24.3m, 28% of equity) and Others (€ 4.4m, 5.1% of equity). The balance between listed assets and Private Equity investments in 1H09 has tilted even more towards the former due to a combination of the Movetis IPO, several write-downs in the Private Equity segment and an organic increase in the value of the listed portfolio.

LISTED PORTFOLIO BREAKDOWN (PER SECTOR)



Source: KBC Securities

DIRECT PE PORTFOLIO BREAKDOWN



Source: KBC Securities

CLEANTECH REMAINS THE MAIN INVESTMENT THEME IN THE LISTED PORTFOLIO

- The listed portfolio has a combined value of € 54.4m (61.5% of total equity), up sharply on the € 36.3m reading at 1H09 (50.7% of total equity), mainly on the back of the Movetis IPO and the increase in equity markets. Listed assets break down in Software & Services (15.6%), Technology & Hardware (11.6%), Pharma & Biotech (3.0%), Healthcare Equipment (2.6%), Electrical & Engineering (17.4%) and Materials (5.8%). Quoted/unquoted assets account for 8.2% of NAV.
- The overall focus remains on investments in cleantech, an area the company defines as “technology-based products and services that provide cleaner or more efficient use of the earth’s natural resources, such as energy, water, air and materials”. The four subsectors are Renewable Energy, Energy Efficiency, Water & Pollution Control and Advanced Materials.
- Quest’s ten biggest listed investments are Movetis (7.7% of NAV), Arcadis (4.2%), Unit 4 Agresso (4.1%), Andritz (3.9%), EVS (3.7%), Tandberg (3.3%), TKH Group (3.1%), Wirecard (2.7%), Pfeiffer Vacuum Technology (2.7%) and Nemetschek (2.6%). These account for 38% of NAV and 59% of the listed portfolio.
- Geographically, the vast majority of listed assets are situated in Belgium and the neighbouring countries: Germany, the Netherlands and the UK. Combined, these account for 75% of the listed portfolio.

PRIVATE EQUITY PORTFOLIO COMBINED WRITE-DOWNS WITH UNLOCKING VALUE

The direct Private Equity stakes have a combined value of € 16.02m and amount to 18.1% of equity. The portfolio of 3rd Party Funds is valued at a combined € 8.34m (9.4% of equity). We have included all unlisted assets in our SOTP in line with the reported carrying values. Quest only put a small amount of cash to work in 2H09, notably to subscribe to a capital increase of CoreOptics and a convertible bond issued by Sphere Medical holding. No longer including Movetis, Quest’s biggest directly-held unlisted stakes are Kiadis and Clear2Pay. The latter enjoyed an upward adjustment of its valuation following Aquiline Capital’s entry in Clear2Pay’s capital (€ 50m). Today, we see few to no triggers capable of further boosting the valuation of any of Quest’s unlisted assets.

5 February 2010

OFF-BALANCE SHEET COMMITMENTS DOWN TO 8.3% OF FINANCIAL ASSETS

Off-balance sheet commitments amount to € 8.3m and relate almost exclusively to the 3rd Party Fund portfolio. This figure accounts for 8.3% of financial assets (down from 15.1% on 1H09) and 34.1% of the total Private Equity portfolio (down versus 39.6% on 1H09). At the analyst meeting, management stuck to its previously announced freeze in new 3rd Party Funds subscriptions. Given that Quest’s net cash level fluctuates constantly due to its highly liquid quoted investment portfolio and the fact that capital calls from 3rd party funds are stretched out over a 2-5 year period, we don’t expect Quest could potentially face problems in honouring these commitments.

MANAGEMENT FEE BEING RENEGOTIATED

Quest is in the process is renewing the annual management fee. We remind that the FY10 fee amounted to € 1.95m (€ 0.16 per share on 31/12/2008), a level that was down 8.5% versus FY08. Management on the analyst meeting didn’t disclose the details of the proposition that is currently on the table, but hinted that the fee would be lowered y/y, both relative to NAV and nominally. We expect the existing maximum global cost ratio of 3.5 % to be maintained. The management fee comes on top of an incentivisation program that is already in place (via (preferential) dividends paid on the A-shares), but since we don’t expect dividend payments in the foreseeable future this program will not kick in.

NO DIVIDEND PAYMENT OVER FY09 EARNINGS

Even though the FY09 results were written in black ink, € 26.5m of carried-over losses were still included on Quest’s balance sheet at 31 December 2009. Management said it will not propose to incorporate these losses into equity, which means it will not be able to pay out dividends or to allocate fresh capital to a share buyback program.

ADJUSTED EQUITY VALUE AND DISCOUNT


We currently estimate Quest’s NAV at € 7.36 per share. The share’s currently trading at a discount of 38.8%, which is relatively high compared to the average “holding discount” (which comprises all of the holding & investment companies of our scope). The chart on the left hand below depicts the evolution of the “holding discount” (not including mono-holding companies), while the chart on the right hand side below depicts the historical evolution of Quest’ NAV. An exact reason for the latter’s digression from its average is difficult to give, even when it looks clear that the depth of the Private Equity portfolio, and the potential to unlock value out of it, have decreased sharply towards the end of FY09. We don’t expect the current discount to increase more, but point out that Quest’s NAV is closely bound to the evolution of the overall stock markets; a steady discount doesn’t equal a steady stock price.

LONG-TERM AVERAGE “HOLDING DISCOUNT”



Source: KBC Securities

QUEST’S HISTORIC NAV



Source: KBC Securities

5 February 2010

DISCOUNTS: A SECTOR COMPARISON

Company	Last price	Adjusted equity value	Current discount	Target equity value	Target discount
Ackermans	50.08	65.39	23.4%	65.44	23.5%
KBC Ancora	16.71	24.83	32.7%	24.83	32.7%
Auximines	505.10	547.58	7.8%	561.32	10.0%
BIP Invest Partners	45.00	74.17	39.3%	74.98	40.0%
Bois Sauvage	175.80	248.81	29.3%	257.06	29.3%
Brederode	17.08	24.41	30.0%	24.72	30.9%
GBL	65.63	86.97	24.5%	92.82	29.3%
Gimv	37.76	42.39	10.9%	42.98	10.9%
HAL Trust	75.50	91.34	17.3%	96.99	22.2%
Heineken Holding	29.99	34.90	14.1%	35.00	14.3%
Henex	38.82	51.83	25.1%	55.48	25.1%
KBC Biotech	4.86	7.79	37.6%	8.58	43.3%
Luxempart	215.10	331.54	35.1%	333.13	35.4%
NPM/CNP	36.33	48.23	24.7%	49.25	24.7%
Pargesa	87.60	114.61	23.6%	120.03	27.0%
Punch International	3.47	16.21	78.6%	15.60	77.8%
Quest for Growth	4.50	7.36	38.8%	7.36	38.8%
Reinet Investments	11.01	12.49	11.8%	12.49	11.8%
RHJI	5.91	9.98	40.8%	9.98	40.8%
Sofina	63.94	97.69	34.5%	101.48	37.0%
Solvac	83.10	111.48	25.5%	135.15	38.5%
Texaf	137.50	231.80	40.7%	231.80	40.7%
Tubize	26.03	39.50	34.1%	44.54	41.6%
Average (mono holdings)			23.5%		29.0%
Average (ex-mono holdings)			31.3%		32.3%

Source: KBC Securities

CORPORATE CALENDAR

Reporting date	Subject
03-Mar-2010	NAV update (A)
18-Mar-2010	General Assembly (A)
02-Apr-2010	NAV update (A)
22-Apr-2010	Results 1Q (A)
23-Apr-2010	Analyst Meeting (A)
05-May-2010	NAV update (A)
04-Jun-2010	NAV update (A)
02-Jul-2010	NAV update (A)
22-Jul-2010	Results 1H (A)
23-Jul-2010	Analyst Meeting (A)
06-Aug-2010	NAV update (A)
03-Sep-2010	NAV update (A)
01-Oct-2010	NAV update (A)
28-Oct-2010	Results 3Q (A)
29-Oct-2010	Analyst Meeting (A)
03-Nov-2010	NAV update (A)
03-Dec-2010	NAV update (A)
05-Jan-2011	NAV update (A)

Source: KBC Securities

5 February 2010

FINANCIAL DATA

Income statement (€m)	2005	2006	2007	2008	2009
Sales & operating income	0.0	0.0	0.0	0.0	0.0
Result from operating activities	0.0	0.0	0.0	0.0	0.0
Result from financing activities	0.0	0.0	0.0	0.0	0.0
Result from extraordinary activities	0.0	0.0	0.0	0.0	0.0
Share of result from associates	0.0	0.0	0.0	0.0	0.0
Income taxes	0.0	0.0	0.0	0.0	0.0
Discontinued activities	0.0	0.0	0.0	0.0	0.0
Minorities	0.0	0.0	0.0	0.0	0.0
Share of the group	7.3	21.5	0.6	-48.4	18.1
Adjusted net result	7.3	21.5	0.6	-48.4	18.1
Balance sheet (€m)	2005	2006	2007	2008	2009
Intangible assets & goodwill	0.0	0.0	0.0	0.0	0.0
Tangible assets	0.0	0.0	0.0	0.0	0.0
Participations acc. for under equity method	0.0	0.0	0.0	0.0	0.0
Other financial assets	0.0	0.0	0.0	0.0	0.0
Cash & cash equivalents	0.0	0.0	0.0	0.0	0.0
Other assets	0.0	0.0	0.0	0.0	0.0
Total assets	103.7	117.6	116.5	67.7	85.6
Equity attributable to holders of the parent	103.2	95.9	115.8	67.4	85.4
Minorities	0.0	0.0	0.0	0.0	0.0
Financial debt	0.0	0.0	0.0	0.0	0.0
Other liabilities	0.0	0.0	0.0	0.0	0.0
Total liabilities	110.6	117.6	116.5	67.7	85.6
Net debt	0.0	0.0	0.0	0.0	0.0
Cash flow statement (€m)	2005	2006	2007	2008	2009
Cash flow from operating activities	0.0	0.0	0.0	0.0	0.0
Cash flow from investing activities	0.0	0.0	0.0	0.0	0.0
Dividends paid (consolidated)	0.0	0.0	0.0	0.0	0.0
Other cash flow from financing	0.0	0.0	0.0	0.0	0.0
Fx and changes to the consolidation scope	0.0	0.0	0.0	0.0	0.0
Change in cash & cash equivalents	0.0	0.0	0.0	0.0	0.0
Per share data (€)	2005	2006	2007	2008	2009
Year-end share price (€)	8.88	10.00	8.40	3.15	4.65
Year-end market cap (€m)	84.0	94.6	99.0	37.1	54.8
weighted average # shares	9,459,073	9,459,073	11,789,255	11,789,255	11,789,255
weighted average # shares, diluted	9,459,073	9,459,073	11,789,255	11,789,255	11,789,255
Basic EPS (€)	0.77	2.28	0.05	-4.11	1.53
Diluted EPS (€)	0.77	2.28	0.05	-4.11	1.53
NBV (€)	10.9	10.1	9.8	5.7	7.2
Adjusted equity value	10.9	12.4	9.9	9.9	7.3
Premium (-)/ Discount	18.61%	19.49%	14.89%	14.89%	35.86%
Gross dividend	0.69	1.94	0.05	0.00	0.00
Gross dividend yield	7.77%	19.40%	0.60%	0.00%	0.00%
Ratios	2005	2006	2007	2008	2009
Return on Equity (avg)	11.40%	20.87%	0.65%	-41.81%	26.83%
Total return	12.4%	20.4%	3.4%	-61.9%	47.6%
Pay-out ratio (adjusted net result)	99.9%	100.0%	93.4%	0.0%	0.0%
P/E	11.58	4.39	159.57	-	3.03
P/NBV	0.81	0.99	0.86	0.55	0.64
Statutory data	2005	2006	2007	2008	2009
Result from operating activities	7.2	20.7	0.3	-48.6	16.9
Result from financing activities	0.1	0.9	0.3	0.2	1.2
Result from extraordinary activities	0.0	0.0	0.0	0.0	0.0
Income taxes	0.0	0.0	0.0	0.0	0.0
Profit/loss before tax	7.3	21.5	0.6	-48.4	18.1
Dividend paid (statutory)	-7.2	-21.5	-0.6	0.0	0.0
Financial assets	103.2	117.3	116.1	67.1	85.1
Other assets	0.5	0.3	0.4	0.6	0.5
Total assets	110.6	117.6	116.5	67.7	85.6
Capital and reserves	103.2	95.9	115.8	67.4	85.4
Provisions and deferred taxation	0.0	0.0	0.0	0.0	0.0
Liabilities	7.4	21.6	0.7	0.3	0.1
Total assets	110.6	117.6	116.5	67.7	85.6

Source: KBC Securities

*Historic valuation data are based on historic prices

5 February 2010

DISCLOSURE & DISCLAIMER SECTION

The company disclosures can also be consulted on our website <http://www.kbcsecurities.be/disclosures>.

KBC Securities uses an absolute rating system including terms such as Buy, Accumulate, Hold, Reduce and Sell (see definitions below).

	Definition
BUY	Expected total return (including dividends) of 10% or more over a 6-month period
ACCUMULATE	Expected total return (including dividends) between 0% and 15% over a 6-month period
HOLD	Expected total return (including dividends) between -5% and 5% over a 6-month period
REDUCE	Expected total return (including dividends) between -15% and 0% over a 6-month period
SELL	Expected total return (including dividends) of -10% or worse over a 6-month period

Due to external factors and in exceptional cases, KBC Securities allows the use of ratings such as Accept the Offer, Black Out, No Recommendation or Suspended.

Our analysts assign one of those ratings based on their investment outlook and valuation for the concerned stock. The valuation can be based on different methodologies such as DCF (discounted cash flow), absolute multiples, peer group multiples, sum-of-parts or NAV (Net Asset Value). The valuation is reflected in a 6-month target price. Occasionally, the expected total return may fall outside of these ranges because of price movement and/or volatility. Such deviations will be permitted but will be closely monitored. Investors should carefully read the definitions of all ratings used in each research report. In addition, since the report contains more complete information concerning the analyst's view, investors should carefully read the entire report and not infer its contents from the rating alone. KBC Securities discloses the recommendations of its reports to the issuers before their dissemination. In case the recommendation has been amended following this disclosure, such amendments will be indicated in the concerned report.

Stock rating	% of covered universe	% of covered universe with investment banking relationship during last year
BUY	33.90%	0.00%
ACCUMULATE	39.10%	0.00%
HOLD	23.50%	0.00%
REDUCE	3.50%	0.00%
SELL	0.00%	0.00%

Quest for Growth is a Belgian investment company focused on listed and unlisted growth companies with the objective of converting capital gains into tax-free income through the Privak-structure.

The price target for Quest For Growth is based on following parameters: Estimated Equity Value (NAV)

The risks which may impede the achievement of our price target are: high correlation with technology markets and sensitive to stock market fluctuations, no recurring profit, need to successfully exit unlisted investments, growth is hampered by regularity payout of realised capital gains

Below is an overview of the stock ratings and target price history in the last 12 months for the stock described in this report.

Date	Rating	Target price
07-JAN-10	Accumulate	€ 5.25
13-OCT-09	Buy	€ 5.25
07-SEP-09	Accumulate	€ 4.75
04-JUN-09	Accumulate	€ 4.50
07-MAY-09	Buy	€ 4.50
05-MAR-09	Buy	€ 4.00

KBC Securities will provide periodic updates on companies/industries based on company-specific developments or announcements, market conditions or any other publicly available information.

5 February 2010

KBC Securities NV
Havenlaan 12
Avenue du Port
1080 Brussels
Belgium
+32 2 417 44 04
Regulated by CBFA

KBC Securities UK
111 Old Broad Street
London EC2N 1PH
UK
+44 20 7418 8900
Regulated by FSA

KBC Securities NV Polish Branch
ul. Chmielna 85/87
00-805 Warsaw
Poland
+48 22 581 08 00
Regulated by PFSA

KBC Securities US
140 East 45th Street
2 Grand Central Tower - 42nd Floor
NY 10017-3144 New York
US
+1 212 845 2200
Regulated by NASD

KBC Securities French Branch
Le Centorial
18, rue du Quatre Septembre
75002 Paris
France
+33 1 53 05 35 55
Regulated by AMF

KBC Securities NV Hungarian Branch
7/8 Roosevelt square
1051 Budapest
Hungary
+361 483 4005
Regulated by PSZAF

KBC Securities Romania
11-15 Tipografilor Street
S-Park A2 Building
Bucharest-1
Romania
+40 21 40 84 200
Regulated by CNVM

KBC Securities Patria
Jungmannova 745/24
110 00 Prague 1
Czech Republic
+420 221 424 111
Regulated by CNB

KBC Securities Ukraine
Illinskaya 8
04070 Kiev
Ukraine
+38 044 495 49 00
Regulated by USSMS

BDD KBC Securities a.d.
Cincar Jankova 3
11000 Belgrade
Serbia
+381 11 21 80 856
Regulated by SSEC

KBC Securities
Baltic Investment Company
16 Basteja Blvd.
Riga LV-1050
Latvia
+371 67212400

KBC Securities NV Bulgarian Branch
22 Gotze Delchev Blvd, Entr. 2
1404 Sofia
Bulgaria
Tel: +359 2 858 33 11
Regulated by FSC

Analyst certification: The analysts identified in this report each certify, with respect to the companies or securities that the individual analyses that (i) the views expressed in this publication reflect his or her personal views about the subject companies and securities, and (ii) he or she receives compensation that is based upon various factors, including his or her employer's total revenues, a portion of which are generated by his or her employer's investment banking activities, but not in exchange for expressing the specific recommendation(s) in this report.

This publication has been prepared by KBC Securities NV which is regulated by CBFA (Banking, Finance and Insurance Commission) or one of its European subsidiaries (together "KBC Securities"). This publication is provided for informational purposes only and is not intended to be an offer, or the solicitation of any offer, to buy or sell the securities referred to herein. No part of this publication may be reproduced in any manner without the prior written consent of KBC Securities.

The information herein has been obtained from, and any opinions herein are based upon, sources believed reliable, but neither KBC Securities nor its affiliates represent that it is accurate or complete, and it should not be relied upon as such. All opinions, forecasts, and estimates herein reflect our judgement on the date of this publication and are subject to change without notice.

From time to time, KBC Securities, its principals or employees may have a position in the securities referred to herein or hold options, warrants or rights with respect thereto or other securities of such issuers and may make a market or otherwise act as principal in transactions in any of these securities. Any such persons may have purchased securities referred to herein for their own account in advance of the release of this publication. KBC Securities and principals or employees of KBC Securities may from time to time provide investment banking or consulting services to, or serve as a director of a company being reported on herein.

This publication is provided solely for the information and use of professional investors who are expected to make their own investment decisions without undue reliance on this publication. Investors must make their own determination of the appropriateness of an investment in any securities referred to herein based on the merits and risks involved, their own investment strategy and their legal, fiscal and financial position. Past performance is no guarantee for future results. By virtue of this publication, none of KBC Securities or any of its employees shall be responsible for any investment decision.

KBC Securities has implemented certain in-house procedures known as Chinese walls that aim to prevent the inappropriate dissemination of inside information. E.g. a Chinese wall surrounds the corporate finance department within KBC Securities. Further measures have been taken with regard to the separation of certain activities that could lead to conflicts of interest with other activities within KBC Securities.

In the United States this publication is being distributed to U.S. Persons by KBC Financial Products USA, Inc., which accepts responsibility for its contents. Orders in any securities referred to herein by any U.S. investor should be placed with KBC Financial Products USA, Inc. and not with any of its foreign affiliates. KBC FP USA Inc. and/or its affiliates may own 1% or more of the subject company's common equity securities. KBCFP USA Inc. or its affiliates may have managed or co-managed a public offering of the subject company's securities in the past 12 months, or received compensation for investment banking services from the subject company in the past 12 months, or expect to receive or intend to seek compensation for investment banking services from the subject company in the next three months. Any U.S. recipient of this report that is not a bank or broker-dealer and that wishes to receive further information regarding, or to effect any transaction in, any security discussed in this report, should contact and place orders with KBC Financial Products USA Inc. This report is being distributed in the United States solely to investors that are (i) "major U.S. institutional investors" (within the meaning of SEC Rule 15a-6 and applicable interpretations relating thereto) that are also "qualified institutional buyers" (QIBs) within the meaning of SEC Rule 144A promulgated by the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the "Securities Act") or (ii) investors that are not "U.S. Persons" within the meaning of Regulation S under the Securities Act and applicable interpretations relating thereto. The offer or sale of certain securities in the United States may be made to QIBs in reliance on Rule 144A. Such securities may include those offered and sold outside the United States in transactions intended to be exempt from registration pursuant to Regulation S. This report does not constitute in any way an offer or a solicitation of interest in any securities to be offered or sold pursuant to Regulation S. Any such securities may not be offered or sold to U.S. Persons at this time and may be resold to U.S. Persons only if such securities are registered under the Securities Act of 1933, as amended, and applicable state securities laws, or pursuant to an exemption from registration. The products sold by KBC Financial Products USA, Inc or any affiliate thereof, including KBC Securities or KBC Financial Products UK Limited, are not insured by the FDIC, are not obligations of or guaranteed by KBC Bank NV or its affiliates, and are subject to investment risks, including possible loss of the entire amount invested.

This publication is for distribution in or from the United Kingdom only to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom or any order made thereunder or to investment professionals as defined in Section 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and is not intended to be distributed or passed on, directly or indirectly, to any other class of persons.

This publication is for distribution in Canada only to pension funds, mutual funds, banks, asset managers and insurance companies.

The distribution of this publication in other jurisdictions may be restricted by law, and persons into whose possession this publication comes should inform themselves about, and observe, any such restrictions. In particular this publication may not be sent into or distributed, directly or indirectly, in Japan or to any resident thereof.